Create Your Blog
  1. Home
  2. The Prefilled Syringes Market Is Projected To Grow At An Annualized Rate Of ~5%, Till 2030

The Prefilled Syringes Market Is Projected To Grow At An Annualized Rate Of ~5%, Till 2030

>

The prefilled syringes market is projected to grow at an annualized rate of ~5%, till 2030

Roots Analysis has done a detailed study on Prefilled Syringes, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 800+ page report, which features 800+ figures and 150+ tables, please visit this link

 

Key Market Insights

  • Presently, around 80 types of prefilled syringes are available in the market, and several companies claim to be engaged in the manufacturing of both glass and plastic variants of such versatile drug delivery solutions
  • Over 140 drugs and vaccines have either been marketed or have undergone clinical investigation (since 2013) for delivery via prefilled syringes for the treatment of a variety of disease indications
  • In order to gain a competitive edge in the market, prefilled syringe manufacturers are actively engaged in developing patient friendly products, with improved safety features and solutions
  • The market is also characterized by the presence of many contract service providers, spread across the world, offering fill / finish services in prefilled syringes
  • Several big pharma companies are actively engaged in strengthening their pipeline of injectable drugs across various therapeutic areas
  • An evaluation of 280+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via prefilled syringes in the near future, paving way for new partnerships
  • The current market opportunity is well distributed across different therapeutic areas, molecule types and geographical regions; the market is likely to grow at a steady pace over the coming years
  • Glass, single chamber prefilled syringes dominate the current market; however, the demand for plastic devices is anticipated to witness a relatively higher growth in the foreseen future

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html

 

Table of Contents

 

  1. PREFACE
    1.1. Chapter Overview

1.2. Scope of the Report

1.3. Research Methodology

1.4. Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION TO PREFILLED SYRINGES

3.1. Chapter Overview

3.2. History of Prefilled Syringes

3.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices

3.3.1. Benefits for Healthcare Professionals and End Users

3.3.2. Benefits to Manufacturers

3.3.3. Shift from Existing Dosage Forms to Prefilled Syringes

 

3.4. Prefilled Syringe Components

3.5. Classification of Prefilled Syringes

3.5.1. Classification by Barrel Fabrication Material

3.5.1.1. Glass

3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes

3.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes

 

3.5.1.2. Plastic

3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes

3.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes

3.5.1.2.3. Factors Likely to Drive the Use of Plastic Barrel Prefilled Syringes

 

3.5.2. Classification by Number of Chambers in the Barrel

3.5.3. Classification by Type of Needle System

3.5.4. Classification by Type of Packaging

 

3.6. Critical Attributes of Prefilled Syringe Design

3.7. Manufacturing Prefilled Syringes

3.7.1. Production of Barrels

3.7.1.1. Glass Barrel Prefilled Syringes

3.7.1.2. Plastic Barrel Prefilled Syringes

3.7.2. Production of Syringes

3.7.3. Barrel Siliconization

3.7.4. Syringe Sterilization

3.7.5. Validation of Sterilization

3.7.6. Syringe Filling

3.7.7. Syringe Testing

3.8. Future of Prefilled Syringes

 

4 PREFILLED SYRINGES: MARKET OVERVIEW

4.1.  Chapter Overview

4.2.  Prefilled Syringes: List of Available / Under Development Devices

4.2.1.  Analysis by Type of Barrel Fabrication Material

4.2.2.  Analysis by Number of Barrel Chambers

4.2.3.  Analysis by Type of Needle System

4.2.4.  Analysis by Device Capacity

 

4.3.  Prefilled Syringes: List of Developers

4.3.1.  Analysis by Year of Establishment

4.3.2.  Analysis by Company Size

4.3.3.  Analysis by Geographical Location of Headquarters

4.3.4.  Analysis by Geographical Location of Manufacturing Facilities

 

4.4. Technological Developments in Prefilled Syringes

 

5 PRODUCT COMPETITIVENESS ANALYSIS

5.1.  Chapter Overview

5.2.  Methodology

5.3.  Assumptions and Key Parameters

5.4.  Product Competitiveness Analysis: Prefilled Syringe Systems

5.4.1.  Glass Barrel Prefilled Syringes

5.4.2.  Plastic Barrel Prefilled Syringes

 

6 MANUFACTURERS OF PREFILLED SYRINGES

6.1. Chapter Overview

6.2. Key Prefilled Syringe Manufacturers Based in North America

6.2.1. Becton Dickinson

6.2.1.1. Company Overview

6.2.1.2. Financial Performance

6.2.1.3. Prefilled Technology Solutions

6.2.1.4. Glass Barrel Prefilled Systems

6.2.1.4.1. BD Hypak Prefilled Syringe

6.2.1.4.2. BD Neopak Prefilled Syringe

6.2.1.4.3. BD Hylok Prefilled Syringe

6.2.1.5. Plastic Barrel Prefilled Systems

6.2.1.5.1. BD Sterifill Syringe Systems

6.2.1.6. Other Prefilled Delivery Systems

6.2.1.6.1. BD Uniject

6.2.1.7. Recent Developments

6.2.1.8. Future Outlook

 

6.2.2. West Pharmaceutical

6.2.2.1. Company Overview

6.2.2.2. Financial Performance

6.2.2.3. Prefilled Technology Solutions

6.2.2.4. Plastic Barrel Prefilled Systems

6.2.2.4.1. Daikyo Crystal Zenith Polymer RTU Prefilled Syringe

6.2.2.5. Drug Reconstitution Systems

6.2.2.6. Recent Developments

6.2.2.7. Future Outlook

 

6.3. Key Prefilled Syringe Manufacturers Based in Europe

6.3.1. Gerresheimer

6.3.1.1. Company Overview

6.3.1.2. Financial Performance

6.3.1.3. Prefilled Technology Solutions

6.3.1.4. Glass Barrel Prefilled Systems

6.3.1.4.1. Gx Glass Syringes

6.3.1.5. Plastic Barrel Prefilled Systems

6.3.1.5.1. ClearJect Prefilled syringes

6.3.1.5.2. Gx RTF Clearject Needle Syringe

6.3.1.6. Safety Syringes

6.3.1.6.1. Gx InnoSafe Safety Syringes

6.3.1.7. Self-Injection Devices

6.3.1.8. Recent Developments

6.3.1.9. Future Outlook

 

6.3.2. Ompi

6.3.2.1. Company Overview

6.3.2.2. Financial Performance

6.3.2.3. Glass Barrel Prefilled Systems

6.3.2.3.1. EZ-Fill Syringes

6.3.2.3.1.1. EZ-fill Fina

6.3.2.3.1.2. EZ-fill Nexa

6.3.2.3.1.3. EZ-fill Alba

6.3.2.4. Recent Developments

6.3.2.5. Future Outlook

 

6.3.3. Schott

6.3.3.1. Company Overview

6.3.3.2. Financial Performance

6.3.3.3. Glass Barrel Prefilled Syringes

6.3.3.3.1. syriQ Glass Syringes

6.3.3.4. Plastic Barrel Prefilled Syringes

6.3.3.4.1. TopPac Polymer Syringes

6.3.3.5. Recent Developments

6.3.3.6. Future Outlook

 

6.4. Key Prefilled Syringe Manufacturers in Asia

6.4.1. Nipro (Acquired MGlas)

6.4.1.1. Company Overview

6.4.1.2. Financial Performance

6.4.1.3. Glass Barrel Prefilled Systems

6.4.1.4. Recent Developments

6.4.1.5. Future Outlook

 

6.4.2. WEGO Prefills Pharmaceutical Packaging

6.4.2.1. Company Overview

6.4.2.2. Financial Performance

6.4.2.3. WeGo Glass Prefilled Syringe

6.4.2.4. Weigao Prefilled Flush Syringes

6.4.2.5. Future Outlook

 

6.4.3. Taisei Kako

6.4.3.1. Company Overview

6.4.3.2. Glass Barrel Prefilled Systems

6.4.3.2.1. VF-Syringe

6.4.3.2.1. SIN-Syringe

6.4.3.3. Plastic Barrel Prefilled System

6.4.3.3.1. ClearJect Syringes

6.4.3.3.2. FULJECT Passive Type Syringe

6.4.3.3.3. Ajex Needleless Injection System

6.4.3.4. Future Outlook

 

6.4.4. Terumo

6.4.4.1. Company Overview

6.4.4.2. Financial Performance

6.4.4.3. Plastic Barrel Prefilled Syringe

6.4.4.4. Safety Devices: Add-On Devices

6.4.4.5. Recent Developments

6.4.4.6. Future Outlook

 

6.5. Other Manufacturers

6.5.1. Aguettant

6.5.1.1. Company Overview

6.5.1.2. Prefilled Syringe Portfolio

6.5.1.2.1. Aguettant Prefilled Syringe

6.5.1.3. Recent Developments

 

6.5.2. Arte

6.5.2.1. Company Overview

6.5.2.2. Prefilled Syringe Portfolio

6.5.2.2.1. Dual Chamber Prefillable Syringe

6.5.2.2.2. Single Chamber Prefillable Syringe

 

6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)

6.5.3.1. Company Overview

6.5.3.2. Prefilled Syringe Portfolio

 

6.5.4. Pfizer Injectables

6.5.4.1. Company Overview

6.5.4.2. Prefilled Syringe Portfolio

6.5.4.2.1. ABBOJECT Syringe

6.5.4.2.2. Emergency Syringes

6.5.4.2.3. iSecure Syringe System

 

6.5.5. Shandong Pharmaceutical Glass

6.5.5.1. Company Overview

6.5.5.2. Prefilled Syringe Portfolio

 

6.5.6. Shandong Zibo Minkang Pharmaceutical packing

6.5.6.1. Company Overview

6.5.6.2. Prefilled Syringe Portfolio

 

6.5.7. Vetter Pharma

6.5.7.1. Company Overview

6.5.7.2. Prefilled Syringe Portfolio

6.5.7.2.1. Lyo-Ject  Glass Prefilled Syringe

6.5.7.2.2. Vetter-Ject Safety Device

6.5.7.2.3. V-OVS Safety Device

6.5.7.3. Recent Developments

 

7 NEEDLESTICK INJURIES

7.1. Chapter Overview

7.2. Incidence and Associated Financial Burden

7.3. Government Legislations for Prevention of Needlestick Injuries

 

7.4. Safety Mechanisms Used in Modern Prefilled Syringes

7.4.1. Safety Systems: Add-On Safety Device Manufacturers

7.4.1.1. Becton Dickinson

7.4.1.2. Catalent

7.4.1.3. Terumo

7.4.1.4. Tip-Top

7.4.1.5. West Pharmaceutical

 

7.4.2. Safety Systems: Integrated Safety Device Manufacturers

7.4.2.1. Gerresheimer

7.4.2.2. Injecto

7.4.2.3. MedicalChain International

7.4.2.4. OMPI

7.4.2.5. Owen Mumford

7.4.2.6. SHL Group

7.4.2.7. Taisei Kako

 

8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES

8.1. Chapter Overview

8.2. Regulatory Approval of Combination Products in the US

8.2.1. Overview

8.2.2. Historical Background

8.2.3. Regulatory Bodies and their Role in Product Approval

8.2.4. Regulatory Approval for Prefilled Syringes

 

8.3. Regulatory Approval of Combination Products in Europe

8.3.1. Overview

8.3.2. Regulatory Bodies and their Role in Product Approval

8.3.3. Regulatory Approval for Prefilled Syringes

 

8.4. Regulatory Approval of Combination Products in Canada

8.4.1. Overview

8.4.2. Regulatory Bodies and their Role in Product Approval

8.4.3. Regulatory Approval for Prefilled Syringes

 

8.5. Regulatory Approval of Combination Products in Brazil

8.5.1. Overview

8.5.2. Regulatory Bodies and their Role in Product Approval

8.5.3. Regulatory Approval for Prefilled Syringes

 

8.6. Regulatory Approval of Combination Products in Mexico

8.6.1. Overview

8.6.2. Regulatory Bodies and their Role in Product Approval

8.6.3. Regulatory Approval for Prefilled Syringes

 

8.7. Regulatory Approval of Combination Products in Argentina

8.7.1. Overview

8.7.2. Regulatory Bodies and their Role in Product Approval

8.7.3. Regulatory Approval for Prefilled Syringes

 

8.8. Regulatory Approval of Combination Products in Australia

8.8.1. Overview

8.8.2. Regulatory Bodies and their Role in Product Approval

8.8.3. Regulatory Approval for Prefilled Syringes

 

8.9. Regulatory Approval of Combination Products in Japan

8.9.1. Overview

8.9.2. Regulatory Bodies and their Role in Product Approval

8.9.3. Regulatory Approval for Prefilled syringes

 

8.10. Regulatory Approval of Combination Products in China

8.10.1. Overview

8.10.2. Regulatory Bodies and their Role in Product Approval

8.10.3. Regulatory Approval for Prefilled syringes

 

8.11. Regulatory Approval of Combination Products in India

8.11.1. Overview

8.11.2. Regulatory Bodies and their Role in Product Approval

8.11.3. Regulatory Approval for Prefilled Syringes

 

8.12. Regulatory Approval of Combination Products in South Korea

8.12.1. Overview

8.12.2. Regulatory Bodies and their Role in Product Approval

8.12.3. Regulatory Approval for Prefilled Syringes

 

8.13. Regulatory Approval of Combination Products in Saudi Arabia

8.13.1. Overview

8.13.2. Regulatory Bodies and their Role in Product Approval

8.13.3. Regulatory Approval for Prefilled Syringes

 

8.14. Regulatory Approval of Combination Products in United Arab Emirates

8.14.1. Overview

8.14.2. Regulatory Bodies and their Role in Product Approval

8.14.3. Regulatory Approval for Prefilled Syringes

 

9 PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW

9.1. Chapter Overview

9.2. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019

9.2.1. Analysis by Type of Drug Molecule

9.2.2. Analysis by Approval Year

9.2.3. Analysis by Route of Administration

9.2.4. Analysis by Target Therapeutic Area

9.2.5. Prefilled Syringe Combination Products: Additional Information

9.2.5.1. Analysis by Dose Strength

9.2.5.2. Analysis by Other Approved Dosage Forms

 

9.3. Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2019

9.3.1. Analysis by Type of Drug Molecule

9.3.2. Analysis by Phase of Development

9.3.3. Analysis by Route of Administration

9.3.4. Analysis by Target Therapeutic Area

 

9.4. Prefilled Syringe Combination Products: List of Developers

9.4.1.  Analysis by Year of Establishment

9.4.2.  Analysis by Company Size

9.4.3.  Analysis by Geographical Location of Headquarters

 

9.5. Leading Drugs in Prefilled Syringes

9.6. Other Drugs Available in Prefilled Syringes

9.7. Popular Drugs in Prefilled Syringes: Case Studies

9.7.1. HUMIRA® (Adalimumab), AbbVie / Eisai

9.7.1.1. Target Indications and Available Dosage Forms

9.7.1.2. Shift from Vials to Syringes

9.7.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda

9.7.2.1. Target Indications and Available Dosage Forms

9.7.2.2. Shift from Vials to Syringes

 

10 KEY THERAPEUTIC AREAS

10.1. Chapter Overview

10.1.1. Autoimmune Disorders

10.1.1.1. Approved Injectables

10.1.1.2. Biosimilars

 

10.1.2. Infectious Diseases

10.1.2.1. Antiviral Drugs

10.1.2.1.1. Approved Injectables

10.1.2.1.2. Biosimilars

10.1.2.2. Vaccines

10.1.2.2.1. Approved Injectables

 

10.1.3. Neurological Disorders

10.1.3.1. Approved Injectables

10.1.3.2. Biosimilars

 

10.1.4. Metabolic Disorders

10.1.4.1. Approved Injectables

10.1.4.2. Biosimilars

 

11 PREFILLED SYRINGES: LIKELY DRUG CANDIDATES AND PARTNER  ANALYSIS

11.1. Chapter Overview

11.2. Likely Drug Candidates

11.2.1.  Methodology and Key Parameters

 

11.3. Marketed Drug Candidates

11.3.1.  Most Likely Candidates for Delivery via Prefilled Syringes

11.3.2.  Likely Candidates for Delivery via Prefilled Syringes

11.3.3.  Less Likely Candidates for Delivery via Prefilled Syringes

11.3.4.  Least Likely Candidates for Delivery via Prefilled Syringes

 

11.4.  Clinical Drug Candidates

11.4.1.  Most Likely Candidates for Delivery via Prefilled Syringes

11.4.2.  Likely Candidates for Delivery via Prefilled Syringes

11.4.3.  Less Likely Candidates for Delivery via Prefilled Syringes

11.4.4.  Least Likely Candidates for Delivery via Prefilled Syringes

 

11.5.  Potential Strategic Partners

11.5.1.  Methodology and Key Parameters

11.5.2.  Opportunities in North America

11.5.2.1.  Most Likely Partners for Prefilled Syringes Combination Product Development

11.5.2. 2.  Likely Partners for Prefilled Syringes Combination Product Development

11.5.2.3.  Less Likely Partners for Prefilled Syringes Combination Product Development

11.5.2.4.  Least Likely Partners for Prefilled Syringes Combination Product Development

 

11.5.3.  Opportunities in Europe

11.5.3.1.  Most Likely Partners for Prefilled Syringes Combination Product Development

11.5.3.2.  Likely Partners for Prefilled Syringes Combination Product Development

11.5.3.3.  Less Likely Partners for Prefilled Syringes Combination Product Development

11.5.3.4.  Least Likely Partners for Prefilled Syringes Combination Product Development

 

11.5.4.  Opportunities in Asia-Pacific and Rest of the World

11.5.4.1.  Most Likely Partners for Prefilled Syringes Combination Product Development

11.5.4.2.  Likely Partners for Prefilled Syringes Combination Product Development

11.5.4.3.  Less Likely Partners for Prefilled Syringes Combination Product Development

11.5.4.4.  Least Likely Partners for Prefilled Syringes Combination Product Development

 

12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES

12.1.  Chapter Overview

12.2.  Methodology

12.3.  Top Pharmaceutical Companies

12.3.1.  Analysis by Therapeutic Area

12.3.1.1.  Autoimmune Disorders

12.3.1.2.  Infectious Diseases

12.3.1.3.  Oncological Disorders

12.3.1.4.  Metabolic Disorders

12.3.1.5.  Neurological Disorders

12.3.1.6.  Inflammatory Disorders

12.3.1.7.  Orthopedic Disorders

12.3.1.8.  Others

 

12.3.2.  Analysis by Type of Molecule

12.3.2.1.  Antibodies

12.3.2.2.  Vaccines

12.3.2.3.  Proteins

12.3.2.4.  Others

 

13 SPECIALTY PREFILLED SYRINGES

13.1. Chapter Overview

13.2. Prefilled Flush Syringes

13.2.1. Overview

13.2.2. Prefilled Flush Syringes Available in the Market

13.2.3. Advantages of Prefilled Flush Syringes

 

13.3. Prefilled Diluent Syringes

13.3.1. Overview

13.3.2. Lyophilized Drugs Available in Prefilled Diluent Syringes

13.3.3. Advantages of Prefilled Diluent Syringes

13.4. Contrast Agent Prefilled Syringes

13.4.1. Overview

13.4.2. Contrast Agents Available in Prefilled Syringes

13.4.3. Advantages of Contrast Agent Prefilled Syringes

 

14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES

14.1. Chapter Overview

14.2. Prefilled Syringes For Lyophilized Drugs

14.2.1. Prefilled Diluent Syringes

14.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes

14.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringes

14.2.2.2. Prefilled Dual-Chambered Prefilled Pen Injectors for Lyophilized Drugs

 

14.3. Prefilled Syringes for Ophthalmic Delivery

14.4. Prefilled Syringes for Dermal Fillers

14.5. Multilayer Plastic Prefilled Syringes with Oxygen Barrier

14.6. Prefilled Syringes with Low Particle Formation Risk

14.7. Lubrication Technology for Prefilled Syringes

 

14.8. Advances in Terminal Sterilization of Prefilled Syringes

14.8.1. Noxilizer’s  Nitrogen Dioxide Sterilization Technology

14.9. Prefilled Syringe Usage Aids for patients and Healthcare Providers

 

15 MARKET SIZING AND OPPORTUNITY ANALYSIS

15.1. Chapter Overview

15.2. Scope and Methodology

15.3. Global Prefilled Syringes Market, 2020-2030

15.3.1. Prefilled Syringes Market: Distribution by Therapeutic Area

15.3.1.1. Prefilled Syringes Market: Autoimmune Disorders

15.3.1.2. Prefilled Syringes Market: Infectious Diseases

15.3.1.3. Prefilled Syringes Market: Neurological Disorders

15.3.1.4. Prefilled Syringes Market: Blood Disorders

15.3.1.5. Prefilled Syringes Market: Oncological Disorders

15.3.1.6. Prefilled Syringes Market: Psychiatric Diseases

15.3.1.7. Prefilled Syringes Market: Respiratory Disorders

15.3.1.8. Prefilled Syringes Market: Cardiovascular Disorders

15.3.1.9. Prefilled Syringes Market: Metabolic Disorders

15.3.1.10. Prefilled Syringes Market: Ophthalmic Disorder

15.3.1.11. Prefilled Syringes Market: Orthopedic Disorders

15.3.1.12. Prefilled Syringes Market: Other Diseases

 

15.3.2. Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material

15.3.2.1. Prefilled Syringes Market: Glass Barrel Prefilled Syringes

15.3.2.2. Prefilled Syringes Market: Plastic Barrel Prefilled Syringes

 

15.3.3. Prefilled Syringes Market: Distribution by Type of Chamber System

15.3.3.1. Prefilled Syringes Market: Single Chamber Prefilled Syringes

15.3.3.2. Prefilled Syringes Market: Dual Chamber Prefilled Syringes

 

15.3.4. Prefilled Syringes Market: Distribution by Type of Drug Molecule

15.3.4.1. Prefilled Syringes Market: Antibodies

15.3.4.2. Prefilled Syringes Market: Proteins

15.3.4.3. Prefilled Syringes Market: Peptides

15.3.4.4. Prefilled Syringes Market: Small Molecules

15.3.4.5. Prefilled Syringes Market: Vaccines

 

15.3.5. Prefilled Syringes Market: Distribution by Geography

15.3.5.1. Prefilled Syringes Market: North America

15.3.5.2. Prefilled Syringes Market: Europe

15.3.5.3. Prefilled Syringes Market: Asia Pacific

15.3.5.4. Prefilled Syringes Market: Latin America

15.3.5.5. Prefilled Syringes Market: Middle East and Africa

 

15.3.6. Prefilled Syringes Market: Distribution by Specialty Syringes

15.3.7. Prefilled Syringes Market for Autoimmune Disorders

15.3.7.1. Distribution by Syringe Barrel Material

15.3.7.1.1. Glass Barrel Prefilled Syringes

15.3.7.1.2. Plastic Barrel Prefilled Syringes

15.3.7.2. Distribution by Type of Chamber System

15.3.7.2.1. Single Chamber Prefilled Syringes

15.3.7.2.2. Dual Chamber Prefilled Syringes

15.3.7.3. Distribution by Type of Drug Molecule

15.3.7.3.1. Antibodies

15.3.7.3.2. Proteins

15.3.7.3.3. Small Molecules

15.3.7.4. Distribution by Geography

15.3.7.4.1. North America

15.3.7.4.2. Europe

15.3.7.4.3. Asia Pacific

15.3.7.4.4. Latin America

15.3.7.4.5. Middle East and Africa

 

15.3.8. Prefilled Syringes Market For Infectious Disorders

15.3.8.1. Distribution by Type of Syringe Barrel Material

15.3.8.1.1. Glass Barrel Prefilled Syringes

15.3.8.1.2. Plastic Barrel Prefilled Syringes

15.3.8.2. Distribution by Type of Chamber System

15.3.8.2.1. Single Chamber Prefilled Syringes

15.3.8.2.2. Dual Chamber Prefilled Syringes

15.3.8.3. Distribution by Type of Drug Molecule

15.3.8.3.1. Vaccines

15.3.8.4. Distribution by Geography

15.3.8.4.1. North America

15.3.8.4.2. Europe

15.3.8.4.3. Asia Pacific

15.3.8.4.4. Latin America

15.3.8.4.5. Middle East and Africa

 

15.3.9. Prefilled Syringes Market For Neurological Disorders

15.3.9.1. Distribution by Type of Syringe Barrel Material

15.3.9.1.1. Glass Barrel Prefilled Syringes

15.3.9.1.2. Plastic Barrel Prefilled Syringes

15.3.9.2. Distribution by Type of Chamber System

15.3.9.2.1. Single Chamber Prefilled Syringes

15.3.9.2.2. Dual Chamber Prefilled Syringes

15.3.9.3. Distribution by Type of Drug Molecule

15.3.9.3.1. Antibodies

15.3.9.3.2. Proteins

15.3.9.3.3. Peptides

15.3.9.4. Distribution by Geography

15.3.9.4.1. North America

15.3.9.4.2. Europe

15.3.9.4.3. Asia Pacific

15.3.9.4.4. Latin America

15.3.9.4.5. Middle East and Africa

 

15.3.10. Prefilled Syringes Market For Blood Disorders

15.3.10.1. Distribution by Type of Syringe Barrel Material

15.3.10.1.1. Glass Barrel Prefilled Syringes

15.3.10.1.2. Plastic Barrel Prefilled Syringes

15.3.10.2. Distribution by Type of Chamber System

15.3.10.2.1. Single Chamber Prefilled Syringes

15.3.10.2.2. Dual Chamber Prefilled Syringes

15.3.10.3. Distribution by Type of Drug Molecule

15.3.10.3.1. Proteins

15.3.10.3.2. Small Molecules

15.3.10.4. Distribution by Geography

15.3.10.4.1. North America

15.3.10.4.2. Europe

15.3.10.4.3. Asia Pacific

15.3.10.4.4. Latin America

15.3.10.4.5. Middle East and Africa

 

15.3.11. Prefilled Syringes Market For Oncological Disorders

15.3.11.1. Distribution by Type of Syringe Barrel Material

15.3.11.1.1. Glass Barrel Prefilled Syringes

15.3.11.1.2. Plastic Barrel Prefilled Syringes

15.3.11.2. Distribution by Type of Chamber System

15.3.11.2.1. Single Chamber Prefilled Syringes

15.3.11.2.2. Dual Chamber Prefilled Syringes

15.3.11.3. Distribution by Type of Drug Molecule

15.3.11.3.1. Antibodies

15.3.11.3.2. Proteins

15.3.11.3.3. Peptides

15.3.11.3.4. Small Molecules

15.3.11.3.5. Vaccines

15.3.11.4. Distribution by Geography

15.3.11.4.1. North America

15.3.11.4.2. Europe

15.3.11.4.3. Asia Pacific

15.3.11.4.4. Latin America

15.3.11.4.5. Middle East and Africa

 

15.3.12. Prefilled Syringes Market For Metabolic Disorders

15.3.12.1. Distribution by Type of Syringe Barrel Material

15.3.12.1.1. Glass Barrel Prefilled Syringes

15.3.12.1.2. Plastic Barrel Prefilled Syringes

15.3.12.2. Distribution by Type of Chamber System

15.3.12.2.1. Single Chamber Prefilled Syringes

15.3.12.2.2. Dual Chamber Prefilled Syringes

15.3.12.3. Distribution by Type of Drug Molecule

15.3.12.3.1. Proteins

15.3.12.3.2. Peptides

15.3.12.4. Distribution by Geography

15.3.12.4.1. North America

15.3.12.4.2. Europe

15.3.12.4.3. Asia Pacific

15.3.12.4.4. Latin America

15.3.12.4.5. Middle East and Africa

15.3.13. Prefilled Syringes Market For Other Disorders

15.3.13.1. Distribution by Type of Syringe Barrel Material

15.3.13.1.1. Glass Barrel Prefilled Syringes

15.3.13.1.2. Plastic Barrel Prefilled Syringes

15.3.13.2. Distribution by Type of Chamber System

15.3.13.2.1. Single Chamber Prefilled Syringes

15.3.13.2.2. Dual Chamber Prefilled Syringes

15.3.13.3. Distribution by Type of Drug Molecule

15.3.13.3.1. Antibodies

15.3.13.3.2. Proteins

15.3.13.3.3. Peptides

15.3.13.3.4. Small Molecules

15.3.13.4. Distribution by Geography

15.3.13.4.1. North America

15.3.13.4.2. Europe

15.3.13.4.3. Asia Pacific

15.3.13.4.4. Latin America

15.3.13.4.5. Middle East and Africa

 

16 GROWTH DRIVERS

16.1. Chapter Overview

16.2. Rising Incidence of Chronic Diseases

16.3. Growing Preference for Self-Injection

16.4. Evolving Patient Demographics

16.5. Growth of Biologics and Biosimilars Market

16.6. Changing Pharmaceutical Strategies

16.7. Increasing Focus on Prevention of Needlestick Injuries

16.8. Prefilled Syringes in Autoinjectors and Pen Injectors

 

17 SWOT ANALYSIS

17.1. Chapter Overview

17.2. Strengths

17.3. Weaknesses

17.4. Opportunities

17.5. Threats

17.6. Concluding Remarks

 

18 PREFILLED SYRINGE COMPONENT MANUFACTURERS

18.1. Chapter Overview

18.2. List of Component Manufacturers

18.3. Aptar Pharma (a Part of AptarGroup)

18.3.1. Company Overview

18.3.2. Financial Performance

18.3.3. Product Portfolio

18.3.4. Recent Developments and Future Outlook

 

18.4. West Pharmaceutical

18.4.1. Company Overview

18.4.2. Financial Performance

18.4.3. Product Portfolio

18.4.4. Recent Developments and Future Outlook

 

18.5. Datwyler Sealing Solutions (a Part of Datwyler Group)

18.5.1. Company Overview

18.5.2. Financial Performance

18.5.3. Product Portfolio

18.5.4. Recent Developments and Future Outlook

 

18.6. Lonstroff (a Part of Sumitomo Rubber Industries)

18.6.1. Company Overview

18.6.2. Financial Performance

18.6.3. Product Portfolio

18.6.4. Recent Developments and Future Outlook

 

18.7. Ompi (a Part of Stevanato Group)

18.7.1. Company Overview

18.7.2. Product Portfolio

18.7.3. Recent Developments and Future Outlook

 

18.8. Jiangsu Hualan Pharmaceutical New Material

18.8.1. Company Overview

18.8.2. Product Portfolio

18.8.3. Recent Developments and Future Outlook

 

19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES

19.1. Chapter Overview

19.2. Fill / Finish Processing of Prefilled Syringes

19.2.1. Steps Involved in Fill / Finish Process

19.2.2. Methods of Filling and Stoppering of Prefilled Syringes

19.2.3. Prefilled Syringe Filling Technologies

 

19.3. Outsourcing of Fill / Finish Operations

19.4. Growth Considerations

19.5. Prefilled Syringes: List of Fill / Finish Service Providers

19.5.1. Analysis by Year of Establishment

19.5.2. Analysis by Geographical Location of Headquarters and Type of Drug Molecule

19.5.3. Analysis by Scale of Operation

 

20 CASE STUDY: AUTOINJECTORS

20.1. Chapter Overview

20.2. Autoinjectors: Market Overview

 

20.3. Key Players

20.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)

20.3.1.1. Company Overview

20.3.1.2. Product Portfolio

 

20.3.2. Nuance Designs

20.3.2.1. Company Overview

20.3.2.2. Product Portfolio

 

20.3.3. Owen Mumford

20.3.3.1. Company Overview

20.3.3.2. Product Portfolio

 

20.3.4. Scandinavian Health Limited (SHL) Group

20.3.4.1. Company Overview

20.3.4.2. Product Portfolio

 

20.3.5. Union Medico

20.3.5.1. Company Overview

20.3.5.2. Product Portfolio

 

20.3.6. Ypsomed

20.3.6.1. Company Overview

20.3.6.2. Product Portfolio

 

21 CONCLUDING REMARKS

21.1. Chapter Overview

21.2. Key Takeaways

 

22 INTERVIEW TRANSCRIPTS

22.1. Chapter Overview

22.2. Oval Medical Technologies

22.2.1. Company Snapshot

22.2.2. Interview Transcript: Matthew Young, Founder and Chief Technology Officer

 

22.3. Intas Pharmaceuticals

22.3.1. Company Snapshot

22.3.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer

 

22.4. IDT Biologika

22.4.1. Company Snapshot

22.4.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer

 

22.5. West Pharmaceutical

22.5.1. Company Snapshot

22.5.2. Interview Transcript: Kevin Cancelliere and Tibor Hlobik, Marketing Directors

 

22.6. Lonstroff

22.6.1. Company Snapshot

22.6.2. Interview Transcript: Marco Pederiva, Marketing and Sales Directors

 

22.7. IDEO

22.7.1. Company Snapshot

22.7.2. Interview Transcript: Jesse Fourt, Design Directors

 

22.8. Small-sized Medical Device Company

22.8.1. Interview Transcript: Anonymous, Chief Executive Officer

 

23 APPENDIX 1: TABULATED DATA

 

24 APPENDIX 2: LIST OF COMPANIES

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Share:

Keywords: healthcare,roots analysis,wellness and fitness,information services,market research,research,medical devices,pharma,pharmaceutical,active pharmaceutical ingredient,pharmaceutical product development inc

Comments

FREE BLOG/SBM SITES
Categories

Other related blogs

The benefits of CBD Products

By : THE CBD BLOGS

CBD is perhaps the most broadly utilized wellbeing and health items in America, and however numerous..

The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis

By : Roots Analysis

The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragme..

How IV Hydration Therapy in Desert Hot Springs CA Overcomes Hangovers

By : Sungh Yuna

Hangovers after a fun night in California can make your morning uncomfortable and give you a painful..

How CPR Certification in Imperial Valley CA Increases the Survival Rate of Heart Patients

By : Yourcprmd

Today, a large number of institutes in California impart quality CPR training with the American Hear..